Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 February 2022 | Story Lacea Loader | Photo Sonia Small
Nico Janse van Rensburg
Nico Janse van Rensburg, Senior Director: University Estates, and recipient of the UFS Council Medal.

At a meeting held on 26 November 2021, the Council of the University of the Free State (UFS) approved the awarding of the UFS Council Medal for outstanding service to Nico Janse van Rensburg, Senior Director: University Estates.

 

Building our campuses

Janse van Rensburg completed a BSc Quantity Surveying degree at the UFS in 1989 before joining the institution’s then Department of Physical Planning in 2004, after an impressive career as quantity surveyor. In 2012, he was appointed Senior Director: University Estates, continuously adding value to the infrastructure of our three campuses – totalling more than 500 000 m2 – as well as experimental farms and off-campus entities of more than 1 000 ha.

He has a persistent green approach that not only reduces the UFS’ carbon footprint, but also saves the institution millions of rands in energy savings and maintenance. Indigenous and waterwise gardens greet staff, students, and visitors to all our campuses, while being housed in well-maintained buildings. All newly built facilities on our campuses are based on green building principles, while an overall optimal building management system ensures efficient energy management.

 

Mentorship and skills transfer

University Estates, through its procurement management and the leadership of Janse van Rensburg, is also one of the main drivers behind the UFS’ BBBEE scorecard. He initiated a mentoring and skills transfer strategy by means of joint project appointments, enabling previously disadvantaged firms to eventually be appointed independently for similar projects.

To ensure, among others, aesthetically pleasing buildings that offer value for money, Janse van Rensburg and his team have developed a series of technical manuals that outline material specifications and expectations. Since 2012, he has been instrumental in more than 1 000 projects at the UFS.

The university recognises and commends Janse van Rensburg’s indispensable contribution to creating inclusive and quality spaces on our campuses, where staff, students, and visitors can experience our culture of care. His motto is clearly visible in all the projects he completes: Get things done – within time, budget, quality standards, expectations, and user satisfaction.

“It is an immense privilege to be leading the University Estates team, and I am humbled to be the recipient of this prestigious medal. University Estates is all about teamwork, and an award such as this can only be possible through the commitment, dedication, and support of a very capable team, as well as colleagues throughout the UFS. I would also like to thank our very capable leaders, such as Prof Prakash Naidoo, Vice-Rector: Operations, for his support and guidance. I have learnt a lot on this journey and a lot remains to be learnt. All of this could only be achieved with help that goes beyond one’s own strengths and abilities,” said Janse van Rensburg.”

 

Get things done – within time, budget, quality standards, expectations, and user satisfaction.

The Council Medal will be presented to Janse van Rensburg during a graduation ceremony in 2022.


 

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept